Payment overview · 2025
General Payments
$7,184.14
34 reported records · 13 companies
Healthcare provider profile · identity verified
James N O'Dea, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CINCINNATI, OH · NPI 1013165174
Verified facts
What the public records show
CMS Open Payments records show James N O'Dea, M.D. received $7,184.14 in general payments during 2025 across 34 reported records.
bioMerieux Inc accounted for 91.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| bioMerieux Inc | Unresolved — no canonical attribution shown | $6,559.33 | 91.3% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $161.71 | 2.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $69.96 | 1.0% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $62.16 | 0.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $58.05 | 0.8% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $49.01 | 0.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.65 | 0.6% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $40.64 | 0.6% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $36.48 | 0.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.74 | 0.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.58 | 0.4% | 1 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $21.19 | 0.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.64 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $4,005.00 | 1 |
| Travel and Lodging | $2,237.33 | 5 |
| Food and Beverage | $941.81 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel Normalized: biofire spotfire respiratory sore throat r st panel |
Device | bioMerieux Inc | $6,242.33 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $161.71 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $69.96 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $69.96 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $62.16 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $58.05 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $49.01 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $44.24 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $40.64 | 2 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $36.48 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $36.48 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $31.74 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.83 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.58 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.58 | 1 | 2025 |
Source payment records
|
|||||
| BIOFIRE SPOTFIRE Control Station Normalized: biofire spotfire control station |
Device | bioMerieux Inc | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 56 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 92 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 65 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
65 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 561 | 171 |
| Levothyroxine Sodium | Levothyroxine Sodium | 411 | 107 |
| Gabapentin | Gabapentin | 404 | 85 |
| Lisinopril | Lisinopril | 332 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 290 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 263 | 71 |
| Metformin Hcl | Metformin Hcl | 251 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 246 | 64 |
| Omeprazole | Omeprazole | 223 | 66 |
| Meloxicam | Meloxicam | 206 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 201 | 64 |
| Trazodone Hcl | Trazodone Hcl | 201 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 195 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 184 | 50 |
| Furosemide | Furosemide | 176 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 167 | 34 |
| Montelukast Sodium | Montelukast Sodium | 158 | 38 |
| Simvastatin | Simvastatin | 153 | 50 |
| Bupropion Xl | Bupropion Hcl | 146 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 146 | 37 |
| Clonazepam | Clonazepam | 145 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 142 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 142 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 137 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 132 | 41 |
| Fluoxetine Hcl | Fluoxetine Hcl | 127 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 124 | 33 |
| Sertraline Hcl | Sertraline Hcl | 120 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 117 | 38 |
| Potassium Chloride | Potassium Chloride | 117 | 29 |
| Tramadol Hcl | Tramadol Hcl | 115 | 26 |
| Pregabalin | Pregabalin | 114 | 22 |
| Eliquis | Apixaban | 113 | 20 |
| Alprazolam | Alprazolam | 112 | 19 |
| Allopurinol | Allopurinol | 106 | 29 |
| Buspirone Hcl | Buspirone Hcl | 106 | 24 |
| Losartan Potassium | Losartan Potassium | 105 | 41 |
| Prednisone | Prednisone | 101 | 40 |
| Famotidine | Famotidine | 100 | 26 |
| Ozempic | Semaglutide | 92 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 89 | 24 |
| Ondansetron Odt | Ondansetron | 89 | 23 |
| Diazepam | Diazepam | 88 | 15 |
| Donepezil Hcl | Donepezil Hcl | 81 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 80 | 17 |
| Metformin Hcl Er | Metformin Hcl | 78 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 76 | 19 |
| Lorazepam | Lorazepam | 71 | 23 |
| Atenolol | Atenolol | 67 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 65 | 19 |
| Methylprednisolone | Methylprednisolone | 65 | 50 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 17 |
| Carvedilol | Carvedilol | 61 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 60 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 60 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 19 |
| Baclofen | Baclofen | 57 | 19 |
| Jardiance | Empagliflozin | 56 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 14 |
| Mounjaro | Tirzepatide | 53 | suppressed |
| Glipizide Er | Glipizide | 52 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 49 | 14 |
| Celecoxib | Celecoxib | 48 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | 16 |
| Spironolactone | Spironolactone | 48 | 12 |
| Finasteride | Finasteride | 46 | 13 |
| Mirtazapine | Mirtazapine | 45 | 15 |
| Topiramate | Topiramate | 45 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 44 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 43 | 11 |
| Synthroid | Levothyroxine Sodium | 43 | 15 |
| Promethazine Hcl | Promethazine Hcl | 41 | suppressed |
| Trulicity | Dulaglutide | 41 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 40 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 37 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 36 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 35 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Ezetimibe | Ezetimibe | 35 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | 11 |
| Glipizide | Glipizide | 34 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 23 |
| Valsartan | Valsartan | 34 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | 12 |
| Nystatin | Nystatin | 32 | 19 |
| Fluconazole | Fluconazole | 31 | 17 |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Ketoconazole | Ketoconazole | 30 | 16 |
| Azithromycin | Azithromycin | 29 | 25 |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 29 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Methocarbamol | Methocarbamol | 28 | 12 |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Estradiol | Estradiol | 27 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 22 |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Carbamazepine Er | Carbamazepine | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 16 |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Belsomra | Suvorexant | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 11 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,184.14 · 34 records | bioMerieux Inc | AIRSUPRA, BIOFIRE SPOTFIRE Control Station, BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel, BREZTRI, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, JARDIANCE, Korlym, MOUNJARO, OPSUMIT, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, UPTRAVI, Wegovy, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error